Bioprocess Analyzers Market - By Product (Instruments, Consumables & Accessories), Analysis Type (Concentration Detection, Substrate, & Metabolite Analysis), Application (Antibiotics, Recombinant Proteins, Biosimilars), End-use – Global Forecast (2024 – 2032)

Bioprocess Analyzers Market Size

Bioprocess Analyzers Market size was valued at around USD 2.1 billion in 2023 and is estimated to grow at 15.2% CAGR from 2024 to 2032. Bioprocess analyzers are specialized instruments used in biotechnology and pharmaceutical industries to monitor and analyze various parameters related to biological processes occurring in bioreactors and fermentation systems. These analyzers are essential tools for ensuring product quality and maintaining control over critical parameters. The advancements in biotechnology and bioprocessing are significant driving factors for the market.
 

For instance, according to Elsevier’s report, in 2024, process analytical technology analyzers could measure physical and chemical process factors and key attributes with the goal of optimizing process controls. This technology, in the form of a probe or sensor, is designed to integrate within the pharmaceutical manufacturing line and is coupled with computing equipment to perform chemometric modeling for result interpretation and multilayer statistical control of processes. Thus, helping in optimizing yields by providing accurate data on cell growth, metabolite production, and substrate utilization.
 

Furthermore, growing demand for biopharmaceutical products, increasing demand for biosimilar (market size is estimated to account for USD 122.9 billion by the end of year 2032), rising government initiatives and funding, surge in biologics outsourcing, are the contributing factors stimulating the growth of the market.
 

Bioprocess Analyzers Market Trends

The growing demand for biopharmaceutical products plays a pivotal role in the market. Biopharmaceutical products, such as monoclonal antibodies, vaccines, and recombinant proteins, are often produced through complex bioprocesses involving living cells.
 

• For instance, according to the Pharmaceutical Research and Manufacturers of America, in 2023, the world witnessed the administration of more than 20 billion COVID-19 vaccine doses, surpassing the World Health Organization's (WHO) goal of vaccinating 70% of the population.
   
• The quality of biopharmaceuticals is paramount, as deviations in bioprocessing conditions can impact product purity, efficacy, and safety. Bioprocess analyzers provide real-time data on critical parameters, ensuring that production processes remain within specified quality standards.
   
• Bioprocess analyzers enable data-driven decisions to optimize bioreactor conditions, nutrient feeding, and cell culture growth, thereby enhancing efficiency and productivity. Consequently, biopharmaceutical manufacturers strive to maximize yields while minimizing production time and costs.
   

Bioprocess Analyzers Market Analysis

Based on product, the market is bifurcated into instruments and consumables & accessories. The consumables & accessories segment is estimated to account for USD 3.9 billion by 2032.
 

• Consumables & accessories such as sensors, probes, reagents, calibration standards, and disposable containers, are essential for the operation of bioprocess analyzers. These items are consumed regularly during bioprocess monitoring, necessitating frequent replenishment.
   
• These are critical components that directly contribute to the functionality and accuracy of bioprocess analyzers. For instance, sensors are vital for monitoring parameters like pH, dissolved oxygen, and temperature.
   
• Further, the rising adoption of single-use bioreactors in bioprocessing requires corresponding consumables such as disposable sensors, probes, and various reagents. Consumables are often designed to be compatible with single-use systems, driving their demand.
   

Based on analysis type, the bioprocess analyzers market is divided into substrate analysis, metabolite analysis, and concentration detection. The metabolite analysis segment accounted for USD 936.5 million in 2023.
 

• Metabolite analysis is vital for monitoring the metabolic activity of cells in bioreactors, providing critical insights into cell growth, nutrient consumption, waste production, and the overall metabolic state of cells.
   
• Analyzing metabolites ensures the production of high-quality biopharmaceuticals with desired characteristics. Understanding metabolite concentrations helps optimize bioprocess conditions, leading to improved yield and efficiency.
   
• Moreover, metabolite analysis covers a broad spectrum of compounds, including primary metabolites (such as glucose and lactate) and secondary metabolites (such as antibodies and enzymes). This versatility makes metabolite analysis applicable across various bioprocessing industries, from pharmaceuticals to biofuels.
   
• Thus, continuous advancements in metabolite analysis technologies, such as high-performance liquid chromatography (HPLC) and mass spectrometry, enhance accuracy and sensitivity, thereby propelling the segment growth of the market.
   

Based on application, the bioprocess analyzers market is segmented into antibiotics, recombinant proteins, biosimilars, and other applications. The recombinant proteins segment is estimated to account for USD 2.7 billion revenue by 2032.
 

• Recombinant proteins are widely used in the pharmaceutical industry for developing biologics such as antibodies, cytokines, hormones, and enzymes. These proteins play a crucial role in treating various diseases, including cancer, autoimmune disorders, and genetic disorders.
   
• Increasing approvals and collaborations create a substantial pool for the adoption of these proteins. For instance, in 2022, Algenex received the final audit report confirming compliance with the principles of GMP for active substances of the European Union. This certification validates Algenex's CrisBio technology platform for producing recombinant proteins within the quality standards of the European pharmaceutical industry.
   
• Analyzing recombinant proteins allows for the optimization of bioprocesses, including fermentation and cell culture. Improved efficiency leads to reduced production costs and increased profitability.
   

Based on end-use, the bioprocess analyzers market is segmented into biopharmaceutical companies, CROs & CMOs, research & academic institutes, and other end-users The biopharmaceutical companies segment held a market size of USD 936.3 billion in 2023.
 

• Biopharmaceutical companies heavily rely on bioprocess analyzers for monitoring and controlling critical parameters in bioprocessing. These analyzers ensure the production of high-quality biopharmaceutical products that meet regulatory standards.
   
• Furthermore, bioprocess analyzers provide real-time data, enabling biopharmaceutical companies to optimize bioreactor conditions. Real-time monitoring helps maximize product yield and efficiency.
   
• Analyzing critical parameters with bioprocess analyzers aids in efficient resource utilization. By optimizing processes, companies can reduce waste and minimize production costs.
   
• The global biopharmaceutical market is growing rapidly, leading to an increased demand for bioprocess analyzers.
   

North America bioprocess analyzers market accounted for USD 831.4 million revenue in 2023 and is predicted to witness substantial market growth.
 

• The region is home to a well-established and thriving biopharmaceutical industry, known for its innovation in biotechnology, with many major biopharmaceutical companies headquartered in the U.S.
   
• Rising acquisitions between CROs in the region are creating a demand for bioprocess analyzers. For instance, in 2021, the U.S. Department of Health and Human Services collaborated with Merck to repurpose its existing facilities for rapid large-scale manufacturing of vaccines and therapeutics for use in public health emergencies, including the COVID-19 pandemic.
   
• Furthermore, the region boasts a robust healthcare infrastructure and significant investment in healthcare, driving the need for efficient bioprocessing technologies to produce high-quality biopharmaceutical products.
   

Bioprocess Analyzers Market Share

The bioprocess analyzers industry is highly competitive, marked by several players striving for market dominance. Providers offer comprehensive bioprocessing analyzers and units for analyzing substrates and metabolites. This includes various instruments, consumables & accessories for advanced technology operations in biosimilar, and recombinant proteins. Competition is driven by factors such as the quality and reliability of these instruments, integration capabilities with existing products, and compliance with regulatory standards. Strategic partnerships with biopharmaceutical companies and healthcare networks play a crucial role in market positioning.
 

Bioprocess Analyzers Market Companies

Some of the eminent market participants operating in the bioprocess analyzers industry include:

• Agilent Technologies, Inc.
• Algenax
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Groton Biosystems LLC
• Kaiser Optical Systems, Inc.
• Nova Biomedical
• Randox Laboratories Ltd.
• Sartorius AG
• SYSBIOTECH GmbH
• Thermo Fisher Scientific Inc.
• YSI Inc.
   

Bioprocess Analyzers Industry News:

• In October 2023, Nova Biomedical announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a micro capillary sample mode on the Stat Profile Prime Plus Critical Care analyzer. This device performs on a 11-test panel including pH, PCO2, PO2, Na, K, iCa, iMg, Cl, glucose, lactate, and hematocrit with just 90 microliters of capillary blood, or a complete 22-test profile on just 135 microliters of blood. This launch boosted the market dynamics of the company and increased the demand and sales of the device.
   
• In August 2022, Danaher Corporation entered a partnership with Flownamics to create an automated, online solution for bioprocess culture monitoring and control. The agreement unites the company's Vi-CELL BLU Cell Viability Analyzer with the Seg-Flow S3 Automated On-Line Sampling System from Flownamics. Thus, this strategy increased the product portfolio of the company and generated sales.
   

The bioprocess analyzers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Consumables & accessories

Market, By Analysis Type

• Substrate analysis
• Metabolite analysis
• Concentration detection

Market, By Application

• Antibiotics
• Recombinant proteins
• Biosimilars
• Other applications

Market, By End-use

• Biopharmaceutical companies
• CROs & CMOs
• Research & academic institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa